Cerebral perfusion and gray matter changes associated with chemotherapy-induced peripheral neuropathy

Kelly N H Nudelman, Brenna McDonald, Yang Wang, Dori J. Smith, John D. West, Darren P. O'Neill, Noah R. Zanville, Victoria Champion, Bryan Schneider, Andrew Saykin

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: To investigate the longitudinal relationship between chemotherapy-induced peripheral neuropathy (CIPN) symptoms (sx) and brain perfusion changes in patients with breast cancer. Interaction of CIPN-sx perfusion effects with known chemotherapy-associated gray matter density decrease was also assessed to elucidate the relationship between CIPN and previously reported cancer treatment-related brain structural changes. Methods: Patients with breast cancer treated with (n=24) or without (n=23) chemotherapy underwent clinical examination and brain magnetic resonance imaging at the following three time points: before treatment (baseline), 1 month after treatment completion, and 1 year after the 1-month assessment. CIPN-sx were evaluated with the self-reported Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity four-item sensory-specific scale. Perfusion and gray matter density were assessed using voxel-based pulsed arterial spin labeling and morphometric analyses and tested for association with CIPN-sx in the patients who received chemotherapy. Results: Patients who received chemotherapy reported significantly increased CIPN-sx from baseline to 1 month, with partial recovery by 1 year (P

Original languageEnglish (US)
Pages (from-to)677-683
Number of pages7
JournalJournal of Clinical Oncology
Volume34
Issue number7
DOIs
StatePublished - Mar 1 2016

Fingerprint

Peripheral Nervous System Diseases
Perfusion
Drug Therapy
Brain
Gray Matter
Breast Neoplasms
Second Primary Neoplasms
Therapeutics
Magnetic Resonance Imaging

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cerebral perfusion and gray matter changes associated with chemotherapy-induced peripheral neuropathy. / Nudelman, Kelly N H; McDonald, Brenna; Wang, Yang; Smith, Dori J.; West, John D.; O'Neill, Darren P.; Zanville, Noah R.; Champion, Victoria; Schneider, Bryan; Saykin, Andrew.

In: Journal of Clinical Oncology, Vol. 34, No. 7, 01.03.2016, p. 677-683.

Research output: Contribution to journalArticle

@article{c2115ab0413b457da642dbf418bff3aa,
title = "Cerebral perfusion and gray matter changes associated with chemotherapy-induced peripheral neuropathy",
abstract = "Purpose: To investigate the longitudinal relationship between chemotherapy-induced peripheral neuropathy (CIPN) symptoms (sx) and brain perfusion changes in patients with breast cancer. Interaction of CIPN-sx perfusion effects with known chemotherapy-associated gray matter density decrease was also assessed to elucidate the relationship between CIPN and previously reported cancer treatment-related brain structural changes. Methods: Patients with breast cancer treated with (n=24) or without (n=23) chemotherapy underwent clinical examination and brain magnetic resonance imaging at the following three time points: before treatment (baseline), 1 month after treatment completion, and 1 year after the 1-month assessment. CIPN-sx were evaluated with the self-reported Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity four-item sensory-specific scale. Perfusion and gray matter density were assessed using voxel-based pulsed arterial spin labeling and morphometric analyses and tested for association with CIPN-sx in the patients who received chemotherapy. Results: Patients who received chemotherapy reported significantly increased CIPN-sx from baseline to 1 month, with partial recovery by 1 year (P",
author = "Nudelman, {Kelly N H} and Brenna McDonald and Yang Wang and Smith, {Dori J.} and West, {John D.} and O'Neill, {Darren P.} and Zanville, {Noah R.} and Victoria Champion and Bryan Schneider and Andrew Saykin",
year = "2016",
month = "3",
day = "1",
doi = "10.1200/JCO.2015.62.1276",
language = "English (US)",
volume = "34",
pages = "677--683",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Cerebral perfusion and gray matter changes associated with chemotherapy-induced peripheral neuropathy

AU - Nudelman, Kelly N H

AU - McDonald, Brenna

AU - Wang, Yang

AU - Smith, Dori J.

AU - West, John D.

AU - O'Neill, Darren P.

AU - Zanville, Noah R.

AU - Champion, Victoria

AU - Schneider, Bryan

AU - Saykin, Andrew

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Purpose: To investigate the longitudinal relationship between chemotherapy-induced peripheral neuropathy (CIPN) symptoms (sx) and brain perfusion changes in patients with breast cancer. Interaction of CIPN-sx perfusion effects with known chemotherapy-associated gray matter density decrease was also assessed to elucidate the relationship between CIPN and previously reported cancer treatment-related brain structural changes. Methods: Patients with breast cancer treated with (n=24) or without (n=23) chemotherapy underwent clinical examination and brain magnetic resonance imaging at the following three time points: before treatment (baseline), 1 month after treatment completion, and 1 year after the 1-month assessment. CIPN-sx were evaluated with the self-reported Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity four-item sensory-specific scale. Perfusion and gray matter density were assessed using voxel-based pulsed arterial spin labeling and morphometric analyses and tested for association with CIPN-sx in the patients who received chemotherapy. Results: Patients who received chemotherapy reported significantly increased CIPN-sx from baseline to 1 month, with partial recovery by 1 year (P

AB - Purpose: To investigate the longitudinal relationship between chemotherapy-induced peripheral neuropathy (CIPN) symptoms (sx) and brain perfusion changes in patients with breast cancer. Interaction of CIPN-sx perfusion effects with known chemotherapy-associated gray matter density decrease was also assessed to elucidate the relationship between CIPN and previously reported cancer treatment-related brain structural changes. Methods: Patients with breast cancer treated with (n=24) or without (n=23) chemotherapy underwent clinical examination and brain magnetic resonance imaging at the following three time points: before treatment (baseline), 1 month after treatment completion, and 1 year after the 1-month assessment. CIPN-sx were evaluated with the self-reported Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity four-item sensory-specific scale. Perfusion and gray matter density were assessed using voxel-based pulsed arterial spin labeling and morphometric analyses and tested for association with CIPN-sx in the patients who received chemotherapy. Results: Patients who received chemotherapy reported significantly increased CIPN-sx from baseline to 1 month, with partial recovery by 1 year (P

UR - http://www.scopus.com/inward/record.url?scp=84964378494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964378494&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.62.1276

DO - 10.1200/JCO.2015.62.1276

M3 - Article

VL - 34

SP - 677

EP - 683

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -